Propensity Score-Matched Analysis of Neoadjuvant vs. Adjuvant Therapy in Renal Cell Carcinoma
Our findings suggest a potential advantage of NT in HRL-RCC. Adjuvant immunotherapy was associated with decreased risk of ACM, while in the neoadjuvant group, TMT and IO therapy had similar outcomes. Our findings call for the consideration of a clinical trial to compare the outcomes of AT vs. NT.
Authors
- Edward E. Cherullo
- Viraj A. Master (ORCID: https://orcid.org/0000-0002-7251-142X)
- Giovanni Lughezzani (ORCID: https://orcid.org/0000-0003-3939-4521)
- Nicolò Maria Buffi (ORCID: https://orcid.org/0000-0003-2436-9091)
- Michael A. Liss (ORCID: https://orcid.org/0000-0001-6978-1026)
- Margaret F. Meagher
- Hajime Tanaka (ORCID: https://orcid.org/0000-0003-3632-2901)
- Srinivas Vourganti (ORCID: https://orcid.org/0000-0002-4395-8433)
- Rana R. McKay (ORCID: https://orcid.org/0000-0002-0581-7963)
- Dattatraya Patil (ORCID: https://orcid.org/0000-0002-8242-9825)
- Giuseppe Garofano
- Cesare Saitta (ORCID: https://orcid.org/0009-0009-1947-084X)
- Giacomo Musso (ORCID: https://orcid.org/0000-0001-6024-7177)
- Yasuhisa Fujii (ORCID: https://orcid.org/0000-0002-6761-3229)
- Ithaar Derweesh (ORCID: https://orcid.org/0000-0002-8673-0711)
- Marco Paciotti
Institutions
- Tokyo Medical and Dental University (JP)
- Rush University Medical Center (US)
- Emory Healthcare (US)
- Humanitas University (IT)
- UC San Diego Health System (US)
- Atlanta Medical Center (US)
- University of California San Diego Medical Center (US)
- IRCCS Humanitas Research Hospital (IT)
Publication Details
- Journal
- Cancers
- Published
- 2025-10-29
- DOI
- https://doi.org/10.3390/cancers17213481
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Emory University
- Rush University
- Tokyo Medical and Dental University
- University of California, San Diego